Staphylocoagulase as a hemostatic agent.
作者信息
Mojovic B, Mojovic N, Tager M, Drummond M C
出版信息
Yale J Biol Med. 1969 Aug;42(1):11-20.
Abstract
摘要
相似文献
1
Staphylocoagulase as a hemostatic agent.
Yale J Biol Med. 1969 Aug;42(1):11-20.
2
[Staphylocoagulase and staphylothrombin].
Postepy Hig Med Dosw. 1977 Jan-Feb;31(1):17-31.
3
[The action of staphylocoagulase in blood coagulation].
Ned Tijdschr Geneeskd. 1974 Aug 17;118(33):1268-71.
4
Purification and properties of staphylocoagulase.
Biochim Biophys Acta. 1975 Jan 30;379(1):164-71. doi: 10.1016/0005-2795(75)90018-5.
5
Formation and properties of fibrin clots resulting from staphylocoagulase (SC) action.
Thromb Diath Haemorrh. 1967 Dec 31;18(3-4):475-86.
6
[Reptilase and thrombin-coagulase times in full-term newborns and in the 1st years of life].
Boll Soc Ital Biol Sper. 1975 Oct 15;51(19):1229-33.
7
[Staphylococcal coagulase liberation from toxic-enzyme complex components].
Zh Mikrobiol Epidemiol Immunobiol. 1978 Aug(8):123-6.
8
Evaluation of hemostatic effects of Ankaferd as an alternative medicine.
Altern Med Rev. 2010 Dec;15(4):329-36.
9
Comparative evaluation of systemic coagulants in dogs.
Arzneimittelforschung. 1967 Dec;17(12):1573-4.
10
In vivo and in vitro hemostatic activity of Chromolaena odorata leaf extract.
Pharm Biol. 2012 Sep;50(9):1073-7. doi: 10.3109/13880209.2012.656849.
引用本文的文献
1
The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations.
Biomedicines. 2021 Jul 4;9(7):776. doi: 10.3390/biomedicines9070776.
2
NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
Oncogene. 2018 Jul;37(29):3967-3980. doi: 10.1038/s41388-018-0213-4. Epub 2018 Apr 17.
3
RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
Sci Rep. 2017 Aug 15;7(1):8126. doi: 10.1038/s41598-017-05326-9.
4
Intravascular coagulation in mice by the compact-colony-forming active substance (CCFAS) extracted from a strain of Staphylococcus aureus.
Br J Exp Pathol. 1981 Dec;62(6):583-90.
5
Release of beta-lysin from platelets by thrombin and by a factor produced in heparinized blood.
Infect Immun. 1974 Jan;9(1):179-86. doi: 10.1128/iai.9.1.179-186.1974.
本文引用的文献
1
SPECIFIC COAGULASES OF STAPHYLOCOCCUS AUREUS.
J Exp Med. 1950 Feb 28;91(3):295-307. doi: 10.1084/jem.91.3.295.
2
Concentration, partial purification, properties, and nature of staphylocoagulase.
Yale J Biol Med. 1948 May;20(5):487-501.
3
The experimental production of antibodies to staphylocoagulase.
J Immunol. 1948 Dec;60(4):475-85.
4
Staphylococcal coagulase; mode of action and antigenicity.
J Gen Microbiol. 1952 Feb;6(1-2):95-107. doi: 10.1099/00221287-6-1-2-95.
5
Immunisation against experimental staphylococcal infection with coagulase-rich preparations.
Lancet. 1962 Jun 23;1(7243):1315-8. doi: 10.1016/s0140-6736(62)92420-0.
6
Permanent cannulation of aorta and vena cava in rats and ground squirrels.
J Appl Physiol. 1960 Jul;15:727-8. doi: 10.1152/jappl.1960.15.4.727.
7
Purification of staphylococcal coagulase.
Biochim Biophys Acta. 1960 Jun 3;40:518-22. doi: 10.1016/0006-3002(60)91392-5.
8
INTRAVASCULAR COAGULATION AND FIBRINOLYSIS BY STAPHYLOCOAGULASE. COMPARISON WITH THROMBIN.
Thromb Diath Haemorrh. 1965 Jun 15;13:457-69.
9
STUDIES ON THE PATHOGENESIS OF THROMBOSIS: AN EXPERIMENTAL "HYPERCOAGULABLE" STATE INDUCED BY THE INTRAVENOUS INJECTION OF ELLAGIC ACID.
J Lab Clin Med. 1964 Sep;64:385-98.
10
ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID.
J Lab Clin Med. 1964 Mar;63:359-77.
Zotero 插件